Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3385 | Rivaroxaban 2.5 MG Wiki | 1.00 |
| drug358 | Aspirin 75mg Wiki | 1.00 |
| drug389 | Atorvastatin 40mg Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to characterize the absorption, metabolic pathways of lazertinib, and the excretion of the parent lazertinib and its metabolites, after a single oral dose of 14C-lazertinib in healthy adult male participants.
Description: Cmax is defined as maximum observed plasma concentration.
Measure: Maximum Observed Plasma Concentration (Cmax) of 14C-lazertinib Time: Up to 99 daysDescription: Tmax is defined time to reach the maximum observed concentration.
Measure: Time to Reach Maximum Observed Plasma Concentration (Tmax) of 14C-lazertinib Time: Up to 99 daysDescription: AUC (0-last) is defined as area under the plasma concentration-time curve from time 0 to the time of last observed quantifiable concentration.
Measure: Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC [0-last]) of 14C-lazertinib Time: Up to 99 daysDescription: AUC (0-infinity) is defined as area under the plasma concentration-time curve from time 0 to infinity, calculated as the sum of AUC(0-last)+C(last)/ lambda(z), where C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
Measure: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of 14C-lazertinib Time: Up to 99 daysDescription: Elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve, calculated as 0.693/lambda(z).
Measure: Elimination Half-life (t1/2) of 14C-lazertinib Time: Up to 99 daysDescription: Lambda(z) is defined as apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log transformed concentration vs time data.
Measure: Apparent Terminal Elimination Rate Constant (Lambda[z]) Time: Up to 99 daysDescription: Clearance is a quantitative measure of the rate at which a drug substance is removed from the body, calculated as dose/AUC (0-infinity).
Measure: Total Apparent Clearance (CL/F) of 14C-lazertinib Time: Up to 99 daysDescription: Apparent volume of distribution, calculated as dose/(Lambda(z)*AUC (0-infinity).
Measure: Apparent Volume of Distribution (Vdz/F) of 14C-lazertinib Time: Up to 99 daysDescription: Blood to plasma total radioactivity ratio, calculated as blood total radioactivity/plasma total radioactivity.
Measure: Ratio of Blood to Plasma Total Radioactivity of 14C-lazertinib Time: Up to 99 daysDescription: The ratio of AUC (0-infinity) of 14C-lazertinib to AUC (0-infinity) of total radioactivity in plasma will be assessed.
Measure: Ratio of AUC (0-infinity) of 14C-lazertinib to AUC (0-infinity) of Total Radioactivity in Plasma Time: Up to 99 daysDescription: The ratio of AUC (0-last) of 14C-lazertinib to AUC (0-last) of total radioactivity in plasma will be assessed.
Measure: Ratio of AUC (0-last) of 14C-lazertinib Concentration to AUC (0-last) of Total Radioactivity in Plasma Time: Up to 99 daysDescription: The ratio of Cmax of 14C-lazertinib to Cmax of total radioactivity in plasma will be assessed.
Measure: Ratio of Cmax of 14C-lazertinib to Cmax of Total Radioactivity in Plasma Time: Up to 99 daysDescription: The ratio of 14C-lazertinib concentration to total radioactivity in plasma for each sampling time point will be assessed.
Measure: Ratio of 14C-lazertinib Concentration to Total Radioactivity in Plasma Time: Up to 99 daysDescription: Amount excreted into the urine during a collection interval, where t1 and t2 are the start and end times of the collection interval, and calculated by multiplying the urinary volume with the urinary concentration for that interval.
Measure: Amount of 14C-lazertinib Excreted in Urine (Ae[t1-t2]) Time: Up to 99 daysDescription: Cumulative amount excreted into the urine over the entire collection period, calculated as the sum of Ae's across the collection intervals for each participant.
Measure: Cumulative Amount of 14C-lazertinib Excreted in Urine (Ae) Time: Up to 99 daysDescription: Cumulative amount excreted into the urine, expressed as a percentage of the administered dose, calculated as (Ae divided by dose)*100.
Measure: Percentage of 14C-lazertinib Dose Excreted in Urine (%Ae) Time: Up to 99 daysDescription: The CLr is the renal clearance of the drug, calculated as Ae/AUC(0-infinity).
Measure: Renal Clearance (CLr) of 14C-lazertinib Time: Up to 99 daysDescription: Amount excreted into the feces during a collection interval, where t1 and t2 are the start and end times of the collection interval, and calculated by multiplying the feces weight with the feces concentration for that interval.
Measure: Amount of 14C-lazertinib Excreted in Feces (Fe[t1-t2]) Time: Up to 99 daysDescription: Cumulative amount excreted into the feces over the entire collection period, calculated as the sum of Fe's across the collection intervals for each participant.
Measure: Cumulative Amount of 14C-lazertinib Excreted in Feces (Fe) Time: Up to 99 daysDescription: Cumulative amount excreted into the feces, expressed as a percentage of the administered dose, calculated as (Fe divided by dose)*100.
Measure: Percentage of 14C-lazertinib Dose Excreted in Feces (%Fe) Time: Up to 99 daysDescription: Total recovery, calculated as sum of %Ae and %Fe.
Measure: Total Recovery of 14C-lazertinib Dose in Feces and Urine Time: Up to 99 daysDescription: An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.
Measure: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability Time: Up to 135 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports